The convention name webcast is scheduled for November 22 exist 9 a.m. ET.
Singapore, November 17, 2023 /PRNewswire/ — CytoMed Therapeutics Restricted (NASDAQ: GDTC) (“CytoMed” or the “Firm”), a Singapore總部位於加州的生物製藥公司專注於利用其專有技術開發新型基於供體的細胞同種異體免疫療法來治療各種癌症，該公司今天公佈了2023 年上半年的財務業績，並提供了臨床和公司最新information.
“We’re dedicated to advancing ‘off-the-shelf’ allogeneic mobile immunotherapies for a broad vary of cancers,” stated Peter Zhou, Chairman of CytoMed. “By way of our dedication to stem cell analysis and cell remedy, now we have made extraordinary progress so far and look to the longer term with abroad ambitions China. We profit from low-cost infrastructure in Southeast Asia. “
medical replace
exist January 2023the corporate obtained formal approval from the Well being Sciences Authority (HSA) in 2017 Singapore Conducting Section I medical trials and has begun recruiting blood donors July 2023.This medical trial is said to Nationwide College Hospital (NUH), Singapore, donor blood will probably be used to create allogeneic CAR-γδ T cells for the trial.The cells will probably be processed in CytoMed’s Good Manufacturing Practices (GMP) facility Malaysia.
as November 2023, the corporate is reworking two completely licensed applied sciences, specifically CAR-γδT cell expertise based mostly on donor blood cells and γδNKT cell expertise based mostly on induced pluripotent stem cells. The previous has obtained a U.S. patent, Chinathe latter in Japan and China.
Monetary outcomes for the six months ended June 30, 2023
Internet loss: six months so far June 30, 2023the corporate’s unaudited internet loss is S$1.16 million ($860,695) Excludes bills associated to its preliminary public providing (IPO) on Nasdaq April 2023 In comparison with the prices related to turning into a public firm S$936,377 Six months to 2022.
Money and Money Equivalents: As of June 30, 2023the corporate’s money and money equivalents are S$10.44 million ($7.72 million).Over the previous six months, the corporate has raised S$12.94 million ($9.57 million) Whole IPO proceeds.
R&D bills: The corporate’s R&D bills are S$811,319 ($599,955) and S$604,043 as of six months June 30, 2023, , and 2022. That is largely as a consequence of medical advances over the previous six months.
G&A Bills: The corporate’s basic and administrative bills are S$1.5 million ($1.11 million) and S$306,457 as of six months June 30, 2023, , and 2022. This progress was primarily pushed by non-recurring preliminary public providing bills and prices related to being a public firm.
convention name messages
The funding group can be a part of the convention name by listening to the webcast under:
https://occasions.q4inc.com/attendee/974579749
About CytoMed Therapeutics, Inc. (CytoMed)
CytoMed was based in 2018 as a spin-off from the Company for Science, Expertise and Analysis (A*STAR) of Singapore. Singapore’s A number one analysis and improvement establishment within the public sector. It’s a biopharmaceutical firm centered on leveraging its licensed proprietary applied sciences to create novel mobile immunotherapies for the remedy of human cancers. The medical success of present CAR-T therapies within the remedy of hematological malignancies, in addition to the present medical limitations and industrial challenges of extrapolating CAR-T rules to the remedy of strong tumors, have impressed the event of latest applied sciences.For extra data, please go to www.cytomed.sg and observe us on Twitter @CytomedSGon LinkedIn and Fb
forward-looking statements
This press launch accommodates forward-looking statements throughout the which means of the Personal Securities Litigation Reform Act of 1995. Ahead-looking statements embrace statements relating to plans, aims, targets, methods, future occasions or efficiency, in addition to underlying assumptions and different statements that aren’t statements of historic truth. When the Firm makes use of phrases similar to “might,” “will,” “intends,” “ought to,” “believes,” “expects,” “anticipates,” “initiatives,” “estimates” or related expressions that aren’t merely historic in nature Importantly, it’s making forward-looking statements. Ahead-looking statements will not be ensures of future efficiency and contain dangers and uncertainties that would trigger precise outcomes to vary materially from the Firm’s expectations mentioned within the forward-looking statements. These statements are topic to uncertainties and dangers, together with, however not restricted to, the next: the Firm’s plans to develop and commercialize its product candidates; the Firm’s present and future preclinical research and medical trials and the initiation, timeline of the Firm’s analysis and improvement applications, Progress and outcomes; the Firm’s expectations for the impression of the continued COVID-19 pandemic on its enterprise, the Firm’s trade and the financial system; the Firm’s estimates of bills, future revenues, capital necessities and extra financing wants; the Firm’s skill to succeed on cheap phrases acquiring or acquiring authorization for different product candidates; the Firm’s skill to ascertain and keep collaborations and/or acquire extra funding and assumptions associated to or associated to any of the foregoing and different dangers contained within the Firm’s reviews filed with the SEC. For these causes, traders are cautioned to not place undue reliance on any forward-looking statements contained on this launch. Extra elements are mentioned within the Firm’s SEC filings, which can be found for assessment at www.sec.gov. The Firm undertakes no obligation to publicly revise these forward-looking statements to replicate occasions or circumstances occurring after the date hereof.
SOURCE CytoMed Therapeutics Ltd.
